Monsanto, ToolGen announce licensing agreement for CRISPR – Feedstuffs
|
Monsanto, ToolGen announce licensing agreement for CRISPR
Feedstuffs Monsanto Company and ToolGen Inc., a biotechnology company specializing in genome editing, announced this week that the companies have reached a global licensing agreement for the use of ToolGen’s CRISPR technology platform to develop … |
|
Monsanto Licenses ToolGen CRISPR Technology
GenomeWeb NEW YORK (GenomeWeb) – Monsanto announced today that it has licensed a CRISPR technology platform from Korean biotechnology company ToolGen with the intention of developing agricultural products. The global license provides Monsanto with … Monsanto and ToolGen Announce Global Licensing Agreement on CRISPR Platform, Underscore the Benefits of …GlobeNewswire (press release) |
Medscape |
Immunotherapy in Cancer: Hits and Misses, but Charging Ahead
Medscape After the many success of immunotherapy in various cancer types over the last few years, recent news of failures has come as a bit of a shock. It was a bad day for AstraZeneca in July when stock shares plummeted by more than 16% —the highly … |
Technology Networks |
New Method for 3-D Printing Living Tissues Developed
Laboratory Equipment … components, that could be used to reproducibly produce artificial tissues with appropriate complexity from a range of cells including stem cells,” said Alexander Graham, lead author and 3-D Bioprinting Scientist at OxSyBio (Oxford Synthetic Biology). A New Method of 3D Printing Living TissuesTechnology Networks New method to 3D print living tissues developedOutlook India Scientists develop new way to 3D print LIVING tissue in breakthrough toward regrowing damaged body partsDaily Mail 3DPrint.com –Nature all 19 news articles » |
|
Pharmalittle: Teva looks for partners; BMS suffers an immunotherapy setback
STAT ood morning, everyone, and welcome to the middle of the week. There’s just a few more days until the rush of meetings and deadlines and paperwork can be put aside for a bit of late-summer relaxation. So, in the meantime, keep plugging away. I’m Rebecca … |
|
Pharmalittle: Teva looks for partners; BMS suffers an immunotherapy setback
STAT ood morning, everyone, and welcome to the middle of the week. There’s just a few more days until the rush of meetings and deadlines and paperwork can be put aside for a bit of late-summer relaxation. So, in the meantime, keep plugging away. I’m Rebecca … |